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Abstract: We sought to determine the prevalence of dog erythrocyte 
antigen (DEA) 1, 4 and 7 and naturally occurring anti-DEA7 antibodies in 
Italian Corso dogs. In addition, we correlated DEAs with different 
epidemiologic variables, compared the prevalence of DEAs against other 
canine populations and assessed the risk of sensitisation and transfusion 
reactions (TRs) following unmatched transfusion. Blood samples from 100 
Corso dogs were evaluated for DEA1, 4, 7 and naturally occurring anti-DEA 
7 antibodies.  
 
Seventy-one percent of samples were DEA 1-negative, 100% tested DEA 4-
positive, and 95% tested DEA 7-negative. Suspected anti-DEA7 antibodies 
were found in 32% dogs. The DEA 1 and 7-negative phenotype was 
significantly more common than in most canine populations. When a 
previously tested Italian canine population was considered as blood 
donors for Corso dogs, the risk of DEA1 sensitisation using DEA 1 untyped 
blood was 29%, and of acute haemolytic TRs after a second untyped DEA 1-
incompatible transfusion was 8%. The potential for delayed TRs between 
DEA 7-negative Corso dogs with suspected naturally occurring anti-DEA7 
antibodies receiving untyped DEA 7-positive blood was 11%. Conversely, 
when Corso dogs were blood donors for the same population, the risk of 
DEA1 sensitisation was 17%, and the risk of an acute haemolytic TR after 
a second DEA 1-incompatible blood transfusion was 3%. Corso dogs can be 
suitable blood donors. Additional studies are needed to clarify whether 
the high prevalence of naturally occurring anti-DEA7 antibodies in this 
breed could increase their risk of delayed TRs when they are blood 
recipients. 
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 2 
Abstract  21 
We sought to determine the prevalence of dog erythrocyte antigen (DEA) 1, 4 and 7 22 
and naturally occurring anti-DEA7 antibodies in Italian Corso dogs. In addition, we 23 
correlated DEAs with different epidemiologic variables, compared the prevalence of DEAs 24 
against other canine populations and assessed the risk of sensitisation and transfusion 25 
reactions (TRs) following unmatched transfusion. Blood samples from 100 Corso dogs were 26 
evaluated for DEA1, 4, 7 and naturally occurring anti-DEA 7 antibodies.  27 
 28 
Seventy-one percent of samples were DEA 1-negative, 100% tested DEA 4-positive, 29 
and 95% tested DEA 7-negative. Suspected anti-DEA7 antibodies were found in 32% dogs. 30 
The DEA 1 and 7-negative phenotype was significantly more common than in most canine 31 
populations. When a previously tested Italian canine population was considered as blood 32 
donors for Corso dogs, the risk of DEA1 sensitisation using DEA 1 untyped blood was 29%, 33 
and of acute haemolytic TRs after a second untyped DEA 1-incompatible transfusion was 34 
8%. The potential for delayed TRs between DEA 7-negative Corso dogs with suspected 35 
naturally occurring anti-DEA7 antibodies receiving untyped DEA 7-positive blood was 11%. 36 
Conversely, when Corso dogs were blood donors for the same population, the risk of DEA1 37 
sensitisation was 17%, and the risk of an acute haemolytic TR after a second DEA 1-38 
incompatible blood transfusion was 3%. Corso dogs can be suitable blood donors. Additional 39 
studies are needed to clarify whether the high prevalence of naturally occurring anti-DEA7 40 
antibodies in this breed could increase their risk of delayed TRs when they are blood 41 
recipients. 42 
 43 
Keywords: Canine blood group; Dog erythrocyte antigen; Italy; Transfusion medicine; 44 
Transfusion reaction. 45 46 
 3 
Introduction 47 
Blood typing prior to canine blood transfusions minimises the risk of a transfusion 48 
reaction (TR) due to blood type incompatibility. Therefore, information on the prevalence of 49 
different blood types in various breeds helps in selection of blood donors for inclusion in a 50 
blood donor program. 51 
 52 
In dogs there are seven internationally recognised blood groups in the dog erythrocyte 53 
antigen (DEA) system (DEA 1, 3, 4, 5, 6, 7, 8) (Vriesendorp et al., 1976). More recently 54 
three additional  blood types have been recognised called Dal (Blais et al., 2007), Kai 1 and 55 
Kai 2 (Euler et al., 2016). However, little is known about many of these blood types and for 56 
some, such as DEA 6 and 8, typing sera no longer exist.  57 
 58 
DEA 1 is the most studied blood type. The prevalence of DEA 1-positive dogs varies 59 
both geographically and among breeds from 100% to <10%, but has been estimated at ~50% 60 
overall internationally (Giger et al., 1995; Novais et al., 1999; Hale et al., 2008; Iazbik et al., 61 
2010; Sinnott Esteve et al., 2011; Ergul Ekiz et al., 2011; Spada et al., 2015a, 2015b, 2016c; 62 
Euler et al., 2016). DEA 1 is the most antigenic blood type for which naturally occurring 63 
antibodies do not exist (Giger et al., 1995; Hale and Wefelmann, 2006; Blais et al., 2009; 64 
Euler et al., 2016) . However, following a DEA 1-incompatible transfusion, the blood 65 
recipient becomes sensitised, and a second DEA 1-incompatible transfusion can result in an 66 
acute, and potentially fatal, haemolytic transfusion reaction (HTR; Giger et al., 1995). 67 
 68 
The DEA 4 blood type has a prevalence of nearly100% in the canine population (Hale 69 
et al., 2008; Iazbik et al., 2010; Sinnott Esteve et al., 2011; Spada et al., 2015a, 2015b, 70 
2016c), but in the rare DEA 4-negative dogs, repeated transfusion with incompatible DEA 4 71 
 4 
blood can lead to a TR (Melzer et al., 2003). 72 
 73 
DEA 7 is not integral to the canine red cell membrane. It is produced elsewhere in the 74 
body in soluble form, secreted into the plasma, and adsorbed onto the cell membrane. The 75 
reported prevalence of DEA 7 varies between 6% and 82% in various canine populations ( 76 
(Giger et al., 1995; Hale et al., 2008; Blais et al., 2009; Iazbik et al., 2010; Kessler et al., 77 
2010; Sinnott Esteve et al., 2011; Spada et al., 2015a, 2015b, 2016c). Naturally occurring 78 
anti–DEA 7 antibodies have been identified in up to 50% of all DEA 7–negative dogs that 79 
have never received transfusions (Giger et al., 1995; Hale and Wefelmann, 2006; Blais et al., 80 
2009; Spada et al., 2016b). The clinical significance of naturally occurring anti-DEA 7 81 
antibodies is unclear as clinical TRs against DEA 7 have not been clearly documented; nor 82 
has there been extensive investigation of the post-transfusion survival of DEA 7 incompatible 83 
RBCs in DEA 7-negative dogs with naturally occurring anti-DEA 7 antibodies. The paucity 84 
of these studies might be explained by the difficulty of the extended canine blood-typing 85 
procedure (limited availability of typing reagents, lack of simple and standardised typing 86 
techniques) and the complexity in administering labelled DEA 7-positive RBCs (e.g., 87 
radiolabeled antigen-positive red cells) to DEA 7-negative recipients and following survival 88 
of these cells in the recipient.  89 
 90 
The Corso dog is an ancient Italian medium-to-large size breed. The breed was 91 
officially recognised by the American kennel club (AKC) in 2010 and is now the 36th most 92 
popular dog breed in America1. In Europe, the Fédération Cynologique Internationale (FCI) 93 
definitively classified this breed in 2007 in Group 2, Pinscher and Schnauzer type, section 2, 94 
                                                        
1 See: American Kennel Club, www.akc.org (Accessed 20 February 2017). 
 5 
Molossoid2. Many characteristics of Corso dogs make them good blood donors: they are 95 
large (>25 kg bodyweight), good-tempered, easy to train, breed and handle, and have readily 96 
accessible jugular veins. To date, no studies have evaluated the prevalence of blood types in 97 
this breed.  98 
 99 
We sought to determine the prevalence of DEA 1, 4 and 7 and naturally occurring 100 
anti-DEA7 antibodies in Italian Corso dogs, to correlate blood types with different 101 
epidemiologic variables, to compare prevalence with DEAs in other canine populations tested 102 
worldwide, and to assess the potential risk of sensitisation and TRs following random, DEA 103 
1- and DEA 7-unmatched transfusions. 104 
 105 
Material and methods 106 
Blood samples 107 
The study used left-over EDTA blood from samples collected from 100 clinically 108 
healthy purebred active blood donors Corso dogs, in Northern and potential blood donors 109 
Corso dogs in Southern Italy during Spring 2016. The blood had originally been collected 110 
during routine blood sampling to test for Leishmania infantum or Dirofilaria immitis 111 
infections, which are endemic in Italy. Blood-typing and alloantibodies studies were 112 
performed at the Veterinary Transfusion Research Laboratory (Laboratorio di Ricerca di 113 
Medicina Emotrasfusionale Veterinaria, REVLab), University of Milan, Milan, Italy. Based 114 
on University of Milan animal use regulations, formal ethical approval was not needed as 115 
dogs were sampled with the informed consent of the owners during routine visits for 116 
prophylactic reasons and owners gave their consent for the use of excess blood after routine 117 
testing be used in further studies. Data on gender, age, origin (Northern or Southern Italy), 118 
                                                        
2 See: Fédération Cynologique Internationale, www.fci.be (Accessed 20 February 2017). 
 6 
the breeder from which they were sourced, coat and eye colour, and transfusion history were 119 
collected for each dog sampled.  120 
 121 
Blood typing  122 
Blood types were assessed on fresh blood or on blood stored at 4-6 °C within 7 days 123 
of blood collection (Brechter, 2005).  124 
 125 
DEA 1 blood type was determined with an immunochromatographic strip technique 126 
using monoclonal antibody (Lab Test DEA 1, Alvedia) following the manufacturer’s 127 
guidelines.  128 
 129 
DEA 4 and DEA 7 blood types were determined with polyclonal antiserum using 130 
agglutination on gel columns as previously described (Kessler et al., 2010; Spada et al., 131 
2015b, 2016c). The polyclonal anti–DEA 4 and 7 antiserum used in the study were purchased 132 
from ABRI (Animal Blood Resources International) and imported to the University of Milan 133 
with the authorisation of the Italian Health Minister (protocol authorisation No. 0024135- 134 
23/09/2015- DGSAF-COD_UO-P).  135 
 136 
Briefly, 25 µL of DEA 7 antisera or 15 µL of DEA 4 antisera were mixed with 25 µL 137 
of a 0.8% RBC suspension (made by suspending 10 µL of the RBC pellet in 1 mL of low 138 
ionic strength solution, LISS, ID-Diluent 2, DiaMed) in the reaction chamber of saline gel 139 
columns (ID-Card NaCl enzyme test and cold agglutinins, DiaMed). For all samples, a 140 
negative control column containing the RBC suspension of interest and saline was included. 141 
The gel columns were incubated at 4 °C for 30 min and thereafter were centrifuged in a 142 
special gel column card centrifuge (ID-Centrifuge 24 S, DiaMed) at 80 x g for 10 min. 143 
 7 
Finally, the gel column cards were evaluated for the presence and strength of agglutination. 144 
The gel cards were visually interpreted and agglutination reactions graded from 0 to 4+ in 145 
accordance with the manufacturer’s instructions as follows (Harmening, 2012): 0, negative, 146 
all RBCs were at the bottom of the column; 1+, very few RBC agglutinates were dispersed in 147 
the lower part of the gel, with most RBCs at the bottom of the tube; 2+, all RBCs were 148 
agglutinated and dispersed in the gel; 3+, some RBC agglutinates were dispersed in the upper 149 
part of the gel and most of the RBCs formed a red line on the surface of the gel; and 4+, all 150 
RBCs formed a red line on top of the gel. Results were interpreted as negative if no 151 
agglutination or 1+ agglutination was present, whereas ≥2+ agglutination reactions were 152 
considered positive (Kessler et al., 2010; Euler et al., 2016). Results were considered valid if 153 
the control was negative. In preliminary tests, all samples were negative for 154 
autoagglutination, so no auto-control (i.e., reaction between dog’s RBC solution and its own 155 
plasma) was performed.  156 
 157 
The prevalence of DEAs in Corso dogs was compared with the prevalence of DEAs in 158 
other canine breeds and populations previously typed for DEA 1, 4 and 7, i.e. Italian blood 159 
donors (Spada et al., 2015a), Brazilian blood donors (Sinnott Esteve et al., 2011), US canine 160 
population (Hale et al., 2008) and populations of different breeds such as Greyhounds (Iazbik 161 
et al., 2010), Spanish Greyhounds (Spada et al., 2015b) and Ibizan Hounds (Spada et al., 162 
2016c). 163 
 164 
Alloantibody study  165 
The presence of naturally occurring anti-DEA 7 alloantibodies in DEA 7-negative 166 
plasma samples was tested using an agglutination on gel technique as previously described 167 
(Blais et al., 2007; Euler et al., 2016; Spada et al., 2016a, 2016b). Briefly, 0.8% RBC-LISS 168 
 8 
suspensions were prepared from one DEA 7–positive, DEA 1–negative, and DEA 4–positive 169 
blood sample. Fifty µL of this 0.8% RBC-LISS suspension and 25 µL plasma from each 170 
DEA 7–negative dog were mixed in the reaction chamber of the gel column and incubated at 171 
37°C for 15 min. Gel columns were centrifuged in the special column gel card centrifuge at 172 
80 x g for 10 min and examined for agglutination strength. Similar to the grading for blood 173 
typing, positive agglutination reactions could be graded from 0 to 4+ according to the 174 
manufacturer’s instructions (Harmening, 2012). Reaction ≥1+ identified samples with 175 
naturally occurring anti-DEA 7 antibodies (Blais et al., 2007; Euler et al., 2016; Spada et al., 176 
2016a, 2016b). 177 
 178 
In human transfusion medicine the specificity, or identity, of an anti-RBC antibody 179 
can be determined by testing a recipient’s serum or plasma with a panel of RBC suspensions 180 
with a known antigenic composition. As a rule, serum or plasma that reacts with an RBC 181 
suspension that is positive for a given antigen, but not with a RBC suspension that is negative 182 
for that antigen, is suspected to contain antibodies against the given antigen (Shulman et al., 183 
2001). Following this rule samples in which agglutination was detected when cross matched 184 
against DEA 7-positive RBCs were then cross-matched against RBCs from one DEA 7–185 
negative dog. Samples that showed agglutination against the DEA 7-positive sample but not 186 
with the DEA 7-negative sample were identified as samples containing suspected anti–DEA 187 
7 antibodies.  188 
 189 
Sensitisation and transfusion reactions risk analysis 190 
The potential probability of a dog becoming sensitised following the first transfusion 191 
of blood that was neither cross-matched nor typed for DEA 1 was calculated using the 192 
following formula as previously described (Novais et al., 1999; Ergul Ekiz et al., 2011; Spada 193 
 9 
et al., 2016c):  194 
(% DEA 1-negative × % DEA 1-positive)/100.   195 
The potential probability of the same dog developing an acute HTR with a second 196 
DEA 1-incompatible transfusion using untyped blood was calculated as:  197 
([% DEA 1-negative ×% DEA 1-positive] × % sensitisation for the first transfusion) /10, 000.  198 
The same calculations were made to estimate the potential risk of DTR due to untyped 199 
DEA 7-positive blood transfused in DEA 7-negative Corso dogs with suspected naturally 200 
occurring anti-DEA 7 antibodies. 201 
 202 
Calculations were made considering the Corso dogs of this study and a population of 203 
Italian blood donors previously blood typed in which prevalence of DEA 1-positive and DEA 204 
7-positive dogs was 40.5% and 33.3%, respectively (Spada et al., 2015a) as both blood 205 
donors and recipients. These were potential probability calculations only.  206 
 207 
Statistical methods 208 
Prevalence was calculated as the proportion of samples testing positive for the 209 
different DEAs and was reported as a percentage with 95% confidence intervals (95%CI).  210 
 211 
The Pearson’s chi-square test or Fisher’s Exact Test were used for statistical 212 
comparison of prevalence of DEA 1, 4 and 7 blood types and suspected naturally occurring 213 
anti-DEA 7 antibodies among different variables i.e. origin (Southern or Northern Italy), the 214 
breeder from which they were sourced, gender, coat and eye colours and to compare the 215 
prevalence of DEAs in Corso dogs with the prevalence of DEAs in other canine breeds or 216 
populations previously typed for DEA 1, 4 and 7.  217 
 218 
 10 
Statistical software (Medcalc Software, version 16.4.3) was used for all analysis and 219 
statistical significance was set at P < 0.01. 220 
 221 
Results 222 
Blood typing was performed on 20 privately owned active blood donors at University 223 
of Milan, Northern Italy and 80 potential blood donors from breeders and private owners of 224 
Italian Corso Dogs in Southern Italy. Median age was 1.6 years (range, 0.8-8.6 years), 63 225 
were female and 37 were male. No dog had a history of blood transfusion.  226 
 227 
The prevalence of DEA 1, DEA 4 and DEA 7-positive samples and strength of 228 
agglutination is reported in Table 1. Sixty-seven dogs (67.0%; 95% confidence intervals [CI], 229 
51.9-85.0%) were negative for both DEA 1 and 7 (but DEA 4-positive). 230 
 231 
Thirty plasma samples from 95 DEA 7-negative dogs (32%; 95% CI, 20.2-42.8%) 232 
contained detectable suspected alloantibodies against DEA 7 with a strength of 233 
agglutination on gel column of 1+ in 11 samples, 2+ in 12 samples, 3+ in seven samples. 234 
The strength of the suspected anti-DEA 7 antibodies was not specifically determined by 235 
titration.  236 
 237 
The DEA 1, 4, 7 phenotypes and presence of suspected naturally occurring anti-DEA 238 
7 antibodies did not vary by gender (male versus female), origin (Northern versus Southern 239 
Italy), coat colour (black, grey, fawn and brindle) or eye colour (brown, yellow, blue), nor 240 
between 10 breeders and 25 private owners. We found no association amongst presence of 241 
different DEAs and amongst DEAs and presence of suspected anti-DEA 7 antibodies (P > 242 
0.01).  243 
 11 
However, DEA 1 and DEA 7 phenotypes differed from those reported previously in 244 
canine populations and other canine breeds (P < 0.01). Corso dogs had a higher prevalence of 245 
DEA 1-negative dogs than other canine populations, with the exception of Greyhounds, 246 
Italian canine blood donors and the canine population from an American study (Hale et al., 247 
2008). Similarly, Corso dogs had a higher prevalence of DEA 7-negative dogs than the other 248 
canine populations, with the exception of Brazilian blood donors and Spanish greyhounds. 249 
Finally, Corso dogs had a higher prevalence of combined DEA 1- and 7-negative dogs (i.e. 250 
DEA 4-positive only) than the other canine populations, with the exception of Greyhounds 251 
(Table 2). 252 
 253 
When a previously tested population of Italian canine blood donors (Spada et al., 254 
2015a) were considered as donors for a Corso dog blood recipient, the risk of DEA 1 255 
sensitisation when using DEA 1 untyped blood was 29%, and the risk of an acute HTR after a 256 
second untyped DEA 1-incompatible blood transfusion was 8%. The potential for a DTR 257 
between DEA 7-negative Corso dogs with suspected naturally occurring anti-DEA 7 258 
antibodies receiving untyped DEA 7-positive blood from Italian dog blood donors was 11%. 259 
Conversely, when Corso dogs were considered as blood donors for the Italian canine 260 
population, the risk of DEA 1 sensitisation when using DEA 1 untyped blood was 17%, and 261 
the risk of an acute HTR after a second DEA 1-incompatible blood transfusion was 3%. 262 
 263 
Discussion 264 
The prevalence of DEAs and suspected naturally occurring antibodies in this 265 
population of Corso dogs has clinical implications. From the perspective of a blood bank 266 
program, it is highly advantageous that most dogs are DEA 1-negative, as DEA 1-blood type 267 
can be used to transfuse both DEA 1-negative and DEA 1-positive recipients.  268 
 12 
The low prevalence of the DEA 7 blood type in Corso dogs is also a favourable 269 
characteristic for blood donors. In fact, in contrast to other canine blood types e.g., DEA 1, 270 
Dal, and the recently discovered Kai 1 and Kai 2 (Giger et al., 1995; Blais et al., 2007; Euler 271 
et al., 2016)  for which there are no naturally occurring antibodies, naturally occurring anti-272 
DEA 7 antibodies exist. Weak, naturally occurring anti–DEA 7 antibodies have been 273 
identified in up to 50% of all DEA 7–negative dogs that have never received transfusions 274 
(Giger et al., 1995; Hale and Wefelmann, 2006; Blais et al., 2009; Spada et al., 2016b) and 275 
although they might result in increased clearance of DEA 7-positive transfused RBCs (Smith, 276 
1991; Hale, 1995; 2012;), neither in vitro haemolysis, HTRs nor neonatal haemolytic 277 
reactions have ever been reported (Blais et al., 2009). Additionally, there is a literature gap on 278 
the significance of naturally occurring anti-DEA 7 antibodies and studies documenting 279 
clinical transfusion reactions due to DEA 7 incompatibilities are dated and were performed 280 
on dogs previously sensitised by blood transfusion and not caused by naturally occurring 281 
anti-DEA 7 antibodies (Swisher and Young, 1961). However, it would not be possible 282 
clinically to detect a slow transfusion reaction, such as that caused by low titres of weak, non-283 
haemolytic, naturally occurring anti-DEA 7 antibodies in a dog with ongoing haemolytic 284 
anaemia. There are no reports of a documented TR due to DEA 7 incompatibility, but 285 
conversely there are no studies that document that DEA 7-positive RBCs transfused into a 286 
DEA 7-negative recipient with naturally occurring anti-DEA 7 antibodies have a normal 287 
lifespan.  288 
 289 
Suspected naturally occurring anti-DEA 7 antibodies were found in approximately 290 
one-third (32%) of Corso dogs tested in this study, a similar finding to recently published 291 
data in the general population where they were detected in 38% of dogs (Spada et al., 292 
2016b). Only weak agglutination reactions were detected with suspected naturally occurring 293 
 13 
anti-DEA 7 antibodies (1+ in 11 samples, 2+ in 12 samples, 3+ in seven samples). Low 294 
agglutination titres are rarely associated with detectable clinical signs in the blood recipient. 295 
However study provides no information on the strength of the anti-DEA 7 alloantibodies, as 296 
this was not specifically determined by titration.  297 
 298 
Sixty-seven percent of all dogs tested were positive for DEA 4 only. The definition of 299 
the ‘universal’ canine donor (referring to DEA 1- and 7-negative dogs, i.e., DEA 4-positive 300 
only) may not be accepted by all clinicians, due to the recent discovery of new blood types 301 
Dal (Blais et al., 2007), Kai 1 and Kai 2 (Euler et al., 2016) which could be implicated in 302 
TRs. DEA 1 and DEA 7 are the blood types that pose most problems in canine blood 303 
transfusion for the reasons cited above; therefore, identification of dogs negative for these 304 
blood types is certainly advantageous when screening for inclusion in blood donor programs. 305 
In the Corso population the prevalence of dogs with DEA 1- and DEA 7- negative and DEA 306 
4-positive phenotype, was greater than in other canine populations previously tested (Hale et 307 
al., 2008; Sinnott Esteve et al., 2011; Spada et al., 2015a, 2015b, 2016c), with the exception 308 
of Greyhounds (Iazbik et al., 2010).   309 
 310 
The prevalence of different DEAs in Corso dogs has a variety of clinical implications 311 
depending on whether dogs are blood donors or recipients. When used as blood donors the 312 
higher prevalence of DEA 1-negative animals reduces the risk of sensitisation and acute 313 
HTRs in the DEA 1-negative recipient, as demonstrated by the lower rate of calculated 314 
potential risk of sensitisation and HTRs when Corso dogs were used as blood donors in 315 
untyped DEA 1 transfusions (17% and 3%, respectively) in comparison with Italian blood 316 
donors (29% and 8%, respectively). However, the actual risk of sensitisation and transfusion 317 
reaction could be different from the calculated risk as development of alloimmunisation and 318 
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subsequent reactions is influenced by a number of factors, such as quantitative differences in 319 
antigen expression, volume of blood administered, frequency of transfusion, and the 320 
recipient’s immune status.  321 
 322 
We did not determine Dal, DEA 3, 5 and the new Kai 1 and Kai 2 blood types (Blais 323 
et al., 2007; Euler et al., 2016); DEA 3 and DEA 5 blood types have prevalences of <25% in 324 
the general canine population (Swisher et al., 1962; Hale, 1995; Hale et al., 2008; Iazbik et 325 
al., 2010; Kessler et al., 2010; Euler et al., 2016;) and naturally occurring antibodies to these 326 
blood types exist in a low percentage of the canine population (Hale and Wefelmann, 2006). 327 
However, it was not possible to investigate these blood types as reagents for DEA 3 and DEA 328 
5, and for Dal and Kai blood types are not commercially available.  329 
 330 
For DEA 4 and DEA 7 blood typing, we used polyclonal antiserum derived from 331 
sensitised dogs, and this could have influenced the consistency of the results, particularly for 332 
DEA 7 blood types in which reactions were not as strong as for DEA 4. Polyclonal antiserum 333 
are heterogeneous and not optimal reagents for use in serologic testing because they can vary 334 
in concentration, serologic properties, and epitope recognition and can contain other 335 
antibodies of unwanted specificity. The ideal serum for serologic testing is a concentrated 336 
suspension of highly specific, well-characterised, uniformly reactive, immunoglobulin 337 
molecules such as monoclonal antibody which contain antibodies of a single specificity 338 
(Brechter, 2005). However only DEA 1 monoclonal antibodies are commercially available 339 
and, to author’s knowledge, all studies that have been performed on DEA 7 rely on the use of 340 
polyclonal DEA 7 antiserum produced after sensitisation of a DEA 7-negative dog with 341 
DEA-7 positive RBC. In this study using polyclonal antiserum, positive agglutination 342 
reactions against DEA 4 (all 4+ agglutination) were much stronger than those against DEA 7 343 
 15 
(1+ and 2+ agglutination). This suggests that the strength of reaction varies according to the 344 
titre and affinity of polyclonal antibodies to the different RBC antigens rather than there 345 
being a defined specificity and strength of reagent.  346 
 347 
To identify naturally occurring anti-DEA 7 antibodies, plasma samples were cross-348 
matched against only one DEA 7-positive RBC sample (and only one DEA 7-negative RBC 349 
sample); it is, therefore, possible that samples that were suspected to contain anti-DEA 7 350 
alloantibodies could have contained other antibodies, such as naturally occurring anti-DEA 3 351 
or anti-DEA 5 antibodies which cross-reacted with the samples. For this reason, in the study 352 
we refer to ‘suspected’ naturally occurring anti-DEA 7 antibodies. 353 
 354 
The fact that all dogs in the study population originated in Italy and there might have 355 
been some interbreeding could have biased the results of prevalence of DEAs. However, 356 
most dogs were geographically distant and from 10 different breeders and from 25 private 357 
owners each having only one dog, so the level of interbreeding should be low. In fact, no 358 
statistically significant association was found between prevalence of DEAs and origin of the 359 
dogs. Furthermore, only 20 active blood donors from one blood bank were included in the 360 
survey, which should limit bias due to inclusion of many blood donors from blood banks 361 
where DEA 1-negative dogs are preferred.  362 
 363 
Conclusions  364 
Corso dogs appear to be an ideal breed to include in canine donor programs, as they 365 
have significantly higher DEA 1 and DEA 7-negative prevalence than most canine 366 
populations previously surveyed. Additional studies are needed to clarify whether the high 367 
 16 
prevalence of suspected naturally occurring anti-DEA7 antibodies in this breed could 368 
increase their risk of DTRs when they are blood recipients.  369 
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Table 1.  485 
Prevalence and strength of agglutination DEA 1, 4, and 7-positive samples in a population of 486 
100 Italian Corso dogs. 487 
DEA % (95% CI) 
Strength of agglutination (%) 
1+ 2+ 3+ 4+ 
1-positive 29 (19.4-41.6) N/A N/A N/A N/A 
4-positive 100 (81.3-121.6) 0 0 0 100 
7-positive 5 (1.6-11.6) 4 5 0 0 
DEA, dog erythrocyte antigen; CI, confidence intervals; N/A, not applicable. 488 
 489 
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Table 2 
491 
C
om
parison of the results of prevalence of blood type D
EA
 1, 4 and 7 in 100 purebred Italian C
orso dogs and D
EA
s prevalence in other canine 
492 
populations tested w
orldw
ide.  
493 
C
anine population 
Investigated 
N
um
ber of 
dogs 
blood typed 
D
EA
 1-positive 
D
EA
 4-positive 
D
EA
 7-positive 
D
EA
 4-positive, 
D
EA
 1 and D
EA
 7-negative 
%
 
P  
%
 
P  
%
 
P  
%
 
P  
C
orso dogs  
(this study) 
100 
29 
N
/A
 
100 
N
/A
 
5 
N
/A
 
67 
N
/A
 
Italian blood donors 
(Spada et al., 2015a) 
(different breeds) 
84  
41 
0.1029 
100 
N
/A
 
33 
<0.0001
a 
38 
0.0001
a 
Spanish greyhounds 
(Spada et al., 2015b) 
205 
(150 for D
EA
 4 
and D
EA
 7) 
55 
0.0003
a 
100 
N
/A
 
8 
0.5662 
47 
0.0067
a 
Ibizan hounds 
(Spada et al., 2016c) 
92 
75 
<0.0001
a 
99 
1.000 
25 
0.0002
a 
17 
< 0.0001
a 
G
reyhounds 
(Iazbik et al., 2010) 
206 
(113 for D
EA
 4) 
13 
0.0092
 a 
100 
N
/A
 
29 
<0.0001
a 
52 
0.0437 
B
razilian blood donors 
(Sinnott Esteve et al., 2011) 
(different breeds) 
100 
 
61 
<0.0001
a 
100 
N
/A
 
17 
0.0129 
14 
<0.0001
a 
U
S canine population 
(H
ale et al., 2008) 
(different breeds) 
9570 
 
42 
0.0762 
98 
0.4773 
20 
0.0028
a 
29 
<0.0001
a 
D
EA
, dog erythrocyte antigen; N
/A
, not applicable 
494 
a Statistically significant (P<0.01) 
495 
 
496 
Highlights  
 
x Information on prevalence of dog erythrocyte antigens (DEAs) is important in selection of 
blood donors. 
 
x Corso dogs fulfil common requirements for blood donors: large size, good-tempered, easy to 
handle during blood collection. 
 
x There is a high prevalence of DEA 1 and DEA 7-negative dogs in the Corso breed. 
 
x The presence of suspected naturally occurring anti-DEA 7 antibodies may be implicated in 
delayed transfusion reactions. 
*Highlights (for review)
